Bio-Thera is responsible for the development and manufacturing of the product, while. Hikma is responsible for the commercialization in the United States.
The agreement includes proposed biosimilars to Ilaris (canakinumab), Kesimpta (ofatumumab) and an additional early-stage undisclosed biosimilar candidate.
The new service will launch at 100 stores throughout Arkansas, Florida, Georgia, North Carolina and Texas, in addition to current operations in Northwest Arkansas and the Dallas-Fort Worth area.